The global AI in Pathology market, valued at $28.75 million in 2025, is projected to grow at a 9.12% CAGR to reach $68.81 million by 2035. Growth is driven by rising demand for digital pathology, AI diagnostics, and improved workflow efficiency through advanced AI technologies. However, geopolitical tensions involving the US, Israel, and Iran are causing supply chain disruptions, IT spending revisions, and operational challenges, particularly in the Middle East. Despite these issues, investment in AI infrastructure remains strong as companies seek automation and remote solutions to mitigate risks. North America leads the market, with significant growth expected in Asia Pacific, while key players include Koninklijke Philips, Roche, and Hologic.
HUTCHMED announced that China's NMPA granted conditional approval for ORPATHYS® (savolitinib) to treat locally advanced or metastatic gastric cancer and gastroesophageal junction adenocarcinoma patients with MET amplification who failed at least two ...
Abbisko Therapeutics and AstraZeneca have formed a strategic collaboration to advance a novel combination therapy for non-small cell lung cancer (NSCLC) involving Abbisko's oral PD-L1 inhibitor lumipodlin and AstraZeneca's EGFR-TKI Tagrisso. The Phas...
